Clinical Trial Update: Safety and Immunogenicity Study of a Virosomal Vaccine Against Recurrent Vulvovaginal Candida Infection [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the safety and immunogenicity of a virosomal vaccine for recurrent vulvovaginal candidiasis. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vulvovaginal Candidiasis

Drugs mentioned

• Pevion Virosomal Vaccine

Snippet

Sponsor: Pevion Biotech Ltd | Conditions: Recurrent Vulvovaginal Candidiasis | Phase 1 | Status: COMPLETED